Literature DB >> 9390035

Expression of the receptor for parathyroid hormone-related protein in normal and malignant breast tissue.

S E Downey1, J Hoyland, A J Freemont, F Knox, J Walls, N J Bundred.   

Abstract

Parathyroid hormone-related protein (PTHrP) is the cause of humoral hypercalcaemia of malignancy and interacts with parathyroid hormone (PTH) receptors. Breast cancer cells produce PTHrP in vitro and in vivo. The breast cancer cell line MCF-7, which products PTHrP and expresses PTHrP receptors, proliferates in response to PTHrP. The aim of these studies was to determine the tissue location of PTHrP/PTH receptors (PTHrPR) in primary breast carcinomas and to establish whether they had the potential to respond to PTHrP. The cellular location of mRNA for the PTHrP/PTH receptor was identified using in situ hybridization in primary breast carcinomas and normal breast tissue. Immunohistochemistry for PTHrP was carried out on the same specimens. Tumours were assessed and scored by two observers using the product of intensity of signal and number of positive tumour cells (possible range 0-9). Tumours were also assessed for Ki-67 expression by counting positive nuclei. Non-malignant ductular epithelium expressed mRNA for the PTHrP receptor (mean score 2.6, range 1-4). Breast carcinomas (mean score 4.4, range 0-9) showed variable expression of PTHrP receptor mRNA: eight tumours were negative, 50 had scores similar to normal breast tissue, and 49 had higher scores for the receptor. Levels of expression of the receptor within the primary breast carcinomas were unrelated to immunohistochemical detection of PTHrP or to any standard prognostic factor. There was a significant (P = 0.05) relationship between Ki-67 and PTHrPR expression in individual tumours. The presence of PTHrP and its receptor in normal breast epithelium and breast carcinomas demonstrates that most breast tumours are able to respond to PTHrP. The Ki-67 data suggest that PTHrP is a potential autocrine growth factor in primary breast carcinoma.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9390035     DOI: 10.1002/(SICI)1096-9896(199710)183:2<212::AID-PATH920>3.0.CO;2-O

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  7 in total

1.  Ets2 and protein kinase C epsilon are important regulators of parathyroid hormone-related protein expression in MCF-7 breast cancer cells.

Authors:  Ralph K Lindemann; Melanie Braig; Craig A Hauser; Alfred Nordheim; Jürgen Dittmer
Journal:  Biochem J       Date:  2003-06-15       Impact factor: 3.857

2.  Nuclear localization of parathyroid hormone-related peptide confers resistance to anoikis in prostate cancer cells.

Authors:  Serk In Park; Laurie K McCauley
Journal:  Endocr Relat Cancer       Date:  2012-05-03       Impact factor: 5.678

3.  Parathyroid hormone-related protein expression, in combination with nodal status, predicts bone metastasis and prognosis of breast cancer patients.

Authors:  Keiichi Takagaki; Tsutomu Takashima; Naoyoshi Onoda; Kenji Tezuka; Eiji Noda; Hidemi Kawajiri; Tetsuro Ishikawa; Kosei Hirakawa
Journal:  Exp Ther Med       Date:  2012-03-21       Impact factor: 2.447

Review 4.  Detection of circulating tumor cells in prostate cancer patients: methodological pitfalls and clinical relevance.

Authors:  Zacharoula Panteleakou; Peter Lembessis; Antigone Sourla; Nikolaos Pissimissis; Aristides Polyzos; Charalambos Deliveliotis; Michael Koutsilieris
Journal:  Mol Med       Date:  2008-12-03       Impact factor: 6.354

Review 5.  The multifaceted actions of PTHrP in skeletal metastasis.

Authors:  Fabiana N Soki; Serk In Park; Laurie K McCauley
Journal:  Future Oncol       Date:  2012-07       Impact factor: 3.404

6.  Parathyroid hormone related peptide and receptor expression in paired primary prostate cancer and bone metastases.

Authors:  A A G Bryden; J A Hoyland; A J Freemont; N W Clarke; N J R George
Journal:  Br J Cancer       Date:  2002-02-01       Impact factor: 7.640

7.  The parathyroid hormone-related protein receptor is expressed in breast cancer bone metastases and promotes autocrine proliferation in breast carcinoma cells.

Authors:  R P Hoey; C Sanderson; J Iddon; G Brady; N J Bundred; N G Anderson
Journal:  Br J Cancer       Date:  2003-02-24       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.